Nasdaq
$0.7400▼ 1.67%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $3.5MShares out 4.7M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
8- 10.1After-hours26.10.02 06:00SCHEDULE 13DOwnership#●●●
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.
Timothy Warbington and Creative Acquisition Corp. have jointly filed a Schedule 13D regarding the securities of Creative Medical Technology Holdings, Inc. This filing formalizes their joint reporting agreement concerning their stake in the company.…more
$0.7400-1.67%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 9.25After-hours26.09.26 07:004Ownership
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.
Insider Timothy Warbington and Creative Acquisition Corp. filed a Form 4 to report changes in their beneficial ownership of Creative Medical Technology Holdings securities. The filing reflects transactions occurring on September 24, 2026, updating the equity holdings of key management and the associated entity.…more
$0.7400-1.67%vs prev closeView filingShare - 9.25After-hours26.09.26 06:008-KKey event
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.
Creative Medical Technology Holdings (CELZ) acquired 4,000,000 shares of BioDefense, Inc. from Creative Acquisition Corp. (CAC) for $200,000 in cash and 1,000,000 shares of CELZ common stock. This transaction increases CELZ's ownership in BioDefense to 80%, making it a subsidiary, and involves a counterparty controlled by CELZ's CEO, Timothy Warbington.…more
$0.7400-1.67%vs prev closeView filingShare
7 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 5d agoPre-market26.10.20 22:15#●●●#●●●
Creative Medical Reports Positive Clinical Data for Ultrasome Knee Osteoarthritis Study…more
Creative Medical announced that its Ultrasome knee osteoarthritis treatment achieved a 93% patient response rate and a 65% reduction in average pain scores in a pilot study. However, these results are from an open-label, single-arm study, and further controlled clinical trials are required for validation.…more
$0.7400-1.67%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 9.25After-hours26.09.26 06:13
●●●●●●●● ●●●●● ●●●●●●
Creative Medical Technology acquired additional shares of BioDefense for $200,000 in cash and 1 million shares of its own stock. This transaction increases the company's ownership to 80% and involves equity dilution.…more
$0.7400-1.67%vs prev closeShareBenzinga - 9.17Pre-market26.09.17 22:00
●●●●●●●● ●●●●● ●●●●●●
Creative Medical Technology Holdings has filed a new U.S. provisional patent to expand intellectual property protection for its Ultrasome™ cell-free regenerative medicine platform. The filing covers various aspects including product composition, manufacturing controls, and potential therapeutic applications.…more
$0.7400-1.67%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report